Quantum BioPharma Whistleblower Reward Program FAQ
Summary
Quantum BioPharma has launched a whistleblower program offering up to $7 million for verifiable evidence of stock manipulation involving the company's shares. This initiative demonstrates the company's commitment to market integrity and transparency while encouraging reporting to regulatory authorities.
What is Quantum BioPharma’s whistleblower program about?
Quantum BioPharma has implemented a public whistleblower policy offering cash rewards of up to $7 million for verifiable evidence of stock manipulation involving the company’s shares. The program encourages reporting to both U.S. SEC and Canadian regulatory authorities.
How much can whistleblowers earn through this program?
Eligible whistleblowers can receive cash rewards of up to USD $7 million for providing verifiable evidence of stock manipulation. The reward is payable from the net proceeds of the company’s ongoing lawsuit.
How does someone submit information to the whistleblower program?
Eligible participants may submit information directly to reward@quantumbiopharma.com or by calling 1-833-571-1811. The information must materially contribute to a final, non-appealable judgment or binding settlement in Quantum BioPharma’s favor.
What conditions must be met to receive the reward?
The reward will be granted if the submitted information materially contributes to a final, non-appealable judgment or binding settlement in Quantum BioPharma’s favor. The payment comes from the net proceeds of the company’s ongoing lawsuit.
Why is Quantum BioPharma implementing this whistleblower program?
The initiative underscores Quantum’s commitment to transparency, accountability, and market integrity. It was approved by the board and audit committee with input from multiple law firms to combat stock manipulation.
What type of company is Quantum BioPharma?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for treating neurodegenerative, metabolic, and alcohol misuse disorders. The company has drug candidates in different stages of development.
Where can I find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/d6YUb.
What is Quantum BioPharma’s lead compound?
Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. This is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
What other business interests does Quantum BioPharma have?
Quantum BioPharma invented unbuzzd™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership and royalty payments. The company also maintains strategic investments through its subsidiary FSD Strategic Investments Inc., representing loans secured by property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 246606